[{"id":"972ad6b2-046a-4952-a809-07b8eb832df8","acronym":"CALGB-40503","url":"https://clinicaltrials.gov/study/NCT00601900","created_at":"2021-01-18T02:13:51.918Z","updated_at":"2025-02-25T16:35:58.371Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","source_id_and_acronym":"NCT00601900 - CALGB-40503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 394","initiation":"Initiation: 09/24/2008","start_date":" 09/24/2008","primary_txt":" Primary completion: 06/30/2014","primary_completion_date":" 06/30/2014","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-06"},{"id":"86bc2743-2583-49c2-a928-b909e0bc7388","acronym":"ATRACTIB","url":"https://clinicaltrials.gov/study/NCT04408118","created_at":"2021-01-18T21:15:30.355Z","updated_at":"2024-07-02T16:34:59.192Z","phase":"Phase 2","brief_title":"First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC","source_id_and_acronym":"NCT04408118 - ATRACTIB","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" ER expression","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 12/07/2023","primary_completion_date":" 12/07/2023","study_txt":" Completion: 12/07/2023","study_completion_date":" 12/07/2023","last_update_posted":"2024-06-04"},{"id":"e2962ecf-0b50-49e6-96a6-e28d8eca2ad1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05877859","created_at":"2023-05-26T15:07:09.164Z","updated_at":"2024-07-02T16:34:59.728Z","phase":"","brief_title":"Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab","source_id_and_acronym":"NCT05877859","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 04/10/2025","primary_completion_date":" 04/10/2025","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-05-31"},{"id":"49b56574-d546-4ca7-a49a-b03317d41c4c","acronym":"ISIdE","url":"https://clinicaltrials.gov/study/NCT05552001","created_at":"2023-09-05T19:11:08.766Z","updated_at":"2024-07-02T16:35:00.022Z","phase":"Phase 3","brief_title":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT05552001 - ISIdE","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • PD-1","pipe":" | ","alterations":" ER expression • PGR expression • ER amplification • PD-1 positive","tags":["HER-2 • ER • PGR • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • PGR expression • ER amplification • PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-30"},{"id":"ac428d9a-273b-4d56-88c0-0d08a880a183","acronym":"TUXEDO-3","url":"https://clinicaltrials.gov/study/NCT05865990","created_at":"2024-01-16T19:18:52.062Z","updated_at":"2024-07-02T16:35:03.380Z","phase":"Phase 2","brief_title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","source_id_and_acronym":"NCT05865990 - TUXEDO-3","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • ERBB3 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • ERBB3 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"c1553d6e-ee80-4192-a7ab-63e94535e0af","acronym":"PRIMED","url":"https://clinicaltrials.gov/study/NCT05520723","created_at":"2022-08-30T20:55:50.589Z","updated_at":"2024-07-02T16:35:03.596Z","phase":"Phase 2","brief_title":"Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED","source_id_and_acronym":"NCT05520723 - PRIMED","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/07/2023","start_date":" 02/07/2023","primary_txt":" Primary completion: 12/14/2025","primary_completion_date":" 12/14/2025","study_txt":" Completion: 12/14/2025","study_completion_date":" 12/14/2025","last_update_posted":"2024-05-15"},{"id":"263dbb50-23c5-46b2-b2ff-1705aa634bb2","acronym":"OPAL","url":"https://clinicaltrials.gov/study/NCT03077841","created_at":"2021-01-18T15:09:46.503Z","updated_at":"2024-07-02T16:35:07.603Z","phase":"Phase 2/3","brief_title":"Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer","source_id_and_acronym":"NCT03077841 - OPAL","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER","pipe":" | ","alterations":" ER positive • ER expression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 928","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-04-25"},{"id":"762b685b-f9ad-4a92-b22c-56def7ff1101","acronym":"","url":"https://clinicaltrials.gov/study/NCT06331104","created_at":"2024-03-26T14:38:14.768Z","updated_at":"2024-07-02T16:35:11.868Z","phase":"","brief_title":"Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone","source_id_and_acronym":"NCT06331104","lead_sponsor":"Changye Zou","biomarkers":" ER","pipe":" | ","alterations":" ER expression • CDKN1B expression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • CDKN1B expression"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 06/14/2012","start_date":" 06/14/2012","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2024-04-02"},{"id":"ac98ef23-c100-4250-a77b-e2d769f12f8d","acronym":"NCI-2020-02940","url":"https://clinicaltrials.gov/study/NCT04445844","created_at":"2021-01-18T21:23:42.652Z","updated_at":"2024-07-02T16:35:11.834Z","phase":"Phase 2","brief_title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","source_id_and_acronym":"NCT04445844 - NCI-2020-02940","lead_sponsor":"Mridula George, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • Zynyz (retifanlimab-dlwr) • Reolysin (pelareorep)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-02"},{"id":"9ce48936-1e04-4872-87f1-b500a0b6dd8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02632448","created_at":"2021-01-18T12:48:12.271Z","updated_at":"2024-07-02T16:35:12.258Z","phase":"Phase 1/2","brief_title":"A Study of LY2880070 in Participants With Advanced or Metastatic Cancer","source_id_and_acronym":"NCT02632448","lead_sponsor":"Esperas Pharma Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • ESP-01"],"overall_status":"Recruiting","enrollment":" Enrollment 229","initiation":"Initiation: 05/16/2016","start_date":" 05/16/2016","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-29"},{"id":"60e95426-6d42-4d16-983e-9c8e2b245921","acronym":"BELLA","url":"https://clinicaltrials.gov/study/NCT04739670","created_at":"2021-02-05T13:56:24.494Z","updated_at":"2024-07-02T16:35:16.792Z","phase":"Phase 2","brief_title":"Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer","source_id_and_acronym":"NCT04739670 - BELLA","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • ER expression • PGR expression","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-01"},{"id":"ae5a0e32-c5dd-4ae6-83e1-84b2f1b61b9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02971761","created_at":"2021-01-18T14:36:31.515Z","updated_at":"2024-07-02T16:35:18.941Z","phase":"Phase 2","brief_title":"Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT02971761","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • ER expression • PGR expression","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ostarine (enobosarm)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 08/16/2022","study_completion_date":" 08/16/2022","last_update_posted":"2024-02-19"},{"id":"a06a1f8c-26c1-4f1d-a722-79204f2c042a","acronym":"RVU120-SOL-021","url":"https://clinicaltrials.gov/study/NCT05052255","created_at":"2022-12-09T16:57:58.006Z","updated_at":"2024-07-02T16:35:19.350Z","phase":"Phase 1/2","brief_title":"RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors","source_id_and_acronym":"NCT05052255 - RVU120-SOL-021","lead_sponsor":"Ryvu Therapeutics SA","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e romaciclib (RVU120)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-14"},{"id":"51ed1ec4-20a5-4c74-aa26-b71e21881c61","acronym":"EstroTEP","url":"https://clinicaltrials.gov/study/NCT03873428","created_at":"2021-01-18T19:05:56.043Z","updated_at":"2024-07-02T16:35:19.520Z","phase":"","brief_title":"Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES","source_id_and_acronym":"NCT03873428 - EstroTEP","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" ER","pipe":" | ","alterations":" ER expression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/18/2025","primary_completion_date":" 10/18/2025","study_txt":" Completion: 10/18/2025","study_completion_date":" 10/18/2025","last_update_posted":"2024-02-13"},{"id":"c55d98dc-4757-49c8-ba40-0336728471cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03564782","created_at":"2021-01-18T17:33:07.799Z","updated_at":"2024-07-02T16:35:20.243Z","phase":"Phase 1","brief_title":"Examining Bioactivity of PVSRIPO in Invasive Breast Cancer","source_id_and_acronym":"NCT03564782","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 06/30/2019","start_date":" 06/30/2019","primary_txt":" Primary completion: 04/11/2022","primary_completion_date":" 04/11/2022","study_txt":" Completion: 04/11/2022","study_completion_date":" 04/11/2022","last_update_posted":"2024-02-08"},{"id":"28d39287-0b6e-47f6-888a-6eb20943d7bf","acronym":"LESS","url":"https://clinicaltrials.gov/study/NCT05297617","created_at":"2022-03-28T13:52:55.256Z","updated_at":"2024-07-02T16:35:20.960Z","phase":"Phase 2","brief_title":"Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk","source_id_and_acronym":"NCT05297617 - LESS","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER expression"],"overall_status":"Recruiting","enrollment":" Enrollment 696","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 11/01/2029","primary_completion_date":" 11/01/2029","study_txt":" Completion: 11/01/2034","study_completion_date":" 11/01/2034","last_update_posted":"2024-02-05"},{"id":"e0be73fa-279d-4fcc-97a5-08ee1e61f087","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949021","created_at":"2023-07-17T14:09:01.100Z","updated_at":"2024-07-02T16:35:28.914Z","phase":"Phase 2","brief_title":"OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer","source_id_and_acronym":"NCT05949021","lead_sponsor":"Mridula George, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER expression • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/07/2023","start_date":" 10/07/2023","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2023-11-17"},{"id":"f61f6186-aed3-4f85-9f8c-28c299c5550f","acronym":"PATHFINDER","url":"https://clinicaltrials.gov/study/NCT04464174","created_at":"2021-01-18T21:27:31.929Z","updated_at":"2024-07-02T16:35:29.196Z","phase":"Phase 2","brief_title":"Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04464174 - PATHFINDER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • capecitabine • Halaven (eribulin mesylate) • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 10/08/2020","start_date":" 10/08/2020","primary_txt":" Primary completion: 11/10/2023","primary_completion_date":" 11/10/2023","study_txt":" Completion: 11/10/2023","study_completion_date":" 11/10/2023","last_update_posted":"2023-11-15"},{"id":"cf6dacb7-4d9a-469d-8ec3-f848632eebdf","acronym":"UTILIZABLE","url":"https://clinicaltrials.gov/study/NCT06125080","created_at":"2023-11-09T16:12:55.735Z","updated_at":"2024-07-02T16:35:29.674Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study","source_id_and_acronym":"NCT06125080 - UTILIZABLE","lead_sponsor":"Huihua Xiong","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 expression • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2023-11-09"},{"id":"2fd9b885-bbba-4045-85ac-083c50be5f8f","acronym":"MIMIR-mTNBC","url":"https://clinicaltrials.gov/study/NCT05742269","created_at":"2023-02-23T15:01:25.619Z","updated_at":"2024-07-02T16:35:34.739Z","phase":"","brief_title":"Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT05742269 - MIMIR-mTNBC","lead_sponsor":"Karolinska University Hospital","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • ER expression • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/20/2027","study_completion_date":" 05/20/2027","last_update_posted":"2023-10-04"},{"id":"3e31567c-6f20-4f50-9139-7f0d892af397","acronym":"SONIA","url":"https://clinicaltrials.gov/study/NCT03425838","created_at":"2021-01-18T16:54:04.918Z","updated_at":"2024-07-02T16:35:39.713Z","phase":"Phase 3","brief_title":"Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer","source_id_and_acronym":"NCT03425838 - SONIA","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER expression • PGR expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1050","initiation":"Initiation: 11/09/2017","start_date":" 11/09/2017","primary_txt":" Primary completion: 03/06/2023","primary_completion_date":" 03/06/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-17"},{"id":"77d54b5c-14c8-4b4d-a137-51c9737d72d0","acronym":"SERENA-3","url":"https://clinicaltrials.gov/study/NCT04588298","created_at":"2021-01-18T21:53:11.603Z","updated_at":"2024-07-02T16:35:41.061Z","phase":"Phase 2","brief_title":"A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer","source_id_and_acronym":"NCT04588298 - SERENA-3","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • ER expression • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • camizestrant (AZD9833)"],"overall_status":"Completed","enrollment":" Enrollment 135","initiation":"Initiation: 11/02/2020","start_date":" 11/02/2020","primary_txt":" Primary completion: 06/19/2023","primary_completion_date":" 06/19/2023","study_txt":" Completion: 06/19/2023","study_completion_date":" 06/19/2023","last_update_posted":"2023-08-03"},{"id":"4a21145c-913f-4666-866a-6508e1e7591f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04174352","created_at":"2021-01-18T20:21:47.085Z","updated_at":"2024-07-02T16:35:45.655Z","phase":"Phase 1","brief_title":"FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer","source_id_and_acronym":"NCT04174352","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" HER-2 negative • ER mutation • ESR1 mutation • ER expression","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ESR1 mutation • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-06-15"},{"id":"b029e0f8-13fb-4ae1-abb0-5815d3c404e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04125277","created_at":"2021-01-18T20:09:17.317Z","updated_at":"2024-07-02T16:35:47.374Z","phase":"","brief_title":"The SONImage Study","source_id_and_acronym":"NCT04125277","lead_sponsor":"University Medical Center Groningen","biomarkers":" ER","pipe":" | ","alterations":" ER expression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-05-23"}]